分组1 - Metagenomi Therapeutics reported a quarterly loss of $0.6 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.58, but an improvement from a loss of $0.63 per share a year ago, indicating an earnings surprise of -4.35% [1] - The company generated revenues of $3.91 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 54.84%, and down from $9.61 million in the same quarter last year [2] - Over the last four quarters, Metagenomi has surpassed consensus EPS estimates two times and topped revenue estimates only once [2] 分组2 - The stock has underperformed the market, losing about 1.2% since the beginning of the year, while the S&P 500 has gained 0.4% [3] - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at -$0.50 on revenues of $8.66 million for the coming quarter, and -$1.71 on revenues of $25.42 million for the current fiscal year [7] - The Medical - Generic Drugs industry, to which Metagenomi belongs, is currently ranked in the bottom 34% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Washington, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41949 Metagenomi Therapeutics, Inc. (Exact Name of registrant as specified in its charter) (State or other jurisdiction of incorpora ...

Exhibit 99.1 Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non- human primates (NHPs) and remains on track for global regulatory submission including investigational new drug application ("IND") in 4Q 2026 Announced corporate name change to Metagenomi Therapeutics, Inc. to reflect Company's strategic evolution $160.8 million in cash, cash equivalents and available-for ...

Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for global regulatory submission including investigational new drug application (“IND”) in 4Q 2026 Announced corporate name change to Metagenomi Therapeutics, Inc. to reflect Company’s strategic evolution $160.8 million in cash, cash equivalents and available-for-sale marketable securities as of December 31, 2025 with runway anticipated to support operations t ...

PresentationEveryone, thank you for joining us in the room and online for TD Cowen's 46th Annual Healthcare Conference. I'm Joe Thome, one of the senior biotech analysts here on the team at TD Cowen. And it's my pleasure to have with me today the team from Metagenomi Therapeutics. We have President and CEO, Jian Irish; and CFO, Pamela Wapnick. So thank you very much. And the presentation is going to start with Jian providing a few overview slides, and then we'll kind of get more into the conversation.Jian I ...

Summary of Metagenomi Therapeutics FY Conference Call Company Overview - **Company Name**: Metagenomi Therapeutics (NasdaqGS:MGX) - **Industry**: Biotechnology, specifically in vivo genome editing - **Focus**: Development of curative genetic medicines, with a primary program for hemophilia A (MGX-001) [5][6] Key Points and Arguments Company Evolution and Strategy - Recently rebranded as Metagenomi Therapeutics to reflect its evolution into a clinical-stage company [5] - Achieved proof of concept for MGX-001, a one-time treatment for hemophilia A, and is prioritizing capital allocation towards this program [5][6] - The company has a library of over 20,000 gene editing systems, demonstrating high specificity and broad genomic targeting [6] Clinical Development and Regulatory Plans - The goal for MGX-001 is to enable endogenous Factor VIII production, normalizing Factor VIII activity levels between 50 to 150 IU/dL [11] - All animals in the dose-range finding study achieved normalized Factor VIII activity levels, with no observed thrombosis risks [11][12] - Plans to submit an Investigational New Drug (IND) application in Q4 of this year, with a focus on safety and efficacy [7][16] Safety and Efficacy - Confidence in the translation of preclinical results to humans, with a favorable safety profile demonstrated through various methods to assess off-target effects [15][16] - The company plans to conduct a global first-in-human single-arm phase I/II study to establish safety and determine effective dose levels [18] Target Patient Population - Initial focus on adult patients, with plans to quickly include pediatric patients due to their potential for significant benefit from a one-time treatment [22][24] - Emphasis on the importance of treating pediatric patients to prevent serious complications and improve quality of life [22][24] Market Differentiation and Economic Considerations - Current hemophilia treatments are expensive, costing over $500,000 per year per patient, with lifetime costs reaching $18 million to $24 million [34][36] - Metagenomi aims to provide a one-time treatment that normalizes Factor VIII activity, addressing unmet medical needs and reducing long-term healthcare burdens [36][38] Pipeline and Partnerships - The company is exploring additional applications for its gene editing technology beyond MGX-001, including potential collaborations [39][48] - Collaboration with Ionis Pharmaceuticals on multiple programs, including a focus on cardiometabolic indications [43][63] Financial Position and Future Outlook - As of the last quarter, the company had approximately $184 million in cash, sufficient to file the IND and proceed into clinical studies [45][46] - The strategic decision to focus on key programs has extended the company's financial runway into Q4 2027 [45] Additional Important Content - The company is actively engaging with the hemophilia community, including key opinion leaders (KOLs) and patient advocacy groups, to prepare for market entry [36][38] - The regulatory landscape is evolving, and the company is learning from past gene therapy programs to ensure compliance and success in its clinical trials [18][53] This summary encapsulates the critical insights from the Metagenomi Therapeutics FY Conference Call, highlighting the company's strategic direction, clinical development plans, market positioning, and financial health.

EMERYVILLE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the 46th Annual TD Cowen Healthcare Conference, being held in Boston, MA, on Monday, March 2, 2026 at 11:10 a.m. ET. The fires ...

Core Viewpoint - MGX Resources faced operational interruptions due to a significant rockfall at Koolan Island, leading to a suspension of mining and a shift in focus towards cash flow generation through alternative means [2]. Group 1: Financial Performance - The financial performance for the December quarter exceeded original expectations, driven by the adjustment of operations to monetize lower-grade stockpile material [3]. - Processing and shipping of low-grade stockpile material is projected to continue until late in the June 2026 quarter [3]. Group 2: Strategic Initiatives - MGX Resources is nearing the completion of the acquisition of the Central Tanami Gold Project, which will facilitate diversification into the precious metals sector [3].

Core Insights - The company has rebranded to Metagenomi Therapeutics, Inc. to reflect its strategic focus on advancing its lead program in hemophilia A and other promising technologies [1][2] - The MGX-001 program has shown curative factor VIII (FVIII) activity in non-human primates, with plans for IND/CTA submissions by the end of 2026 and a first-in-human study anticipated in 2027 [2][4] - The company expects its cash runway to extend through the fourth quarter of 2027, supporting its ongoing development efforts [2][12] Pipeline Advancements - MGX-001 has demonstrated durable FVIII activity over a 19-month study in non-human primates, with no off-target editing detected [6][10] - The company is exploring the potential of the MGX-001 system for treating other secreted protein deficiencies, including Antithrombin (AT-III) deficiency [7][10] - Recent strategic prioritization has strengthened the company's balance sheet and focused its pipeline on high-value therapeutic programs [12] Corporate Updates - The company appointed Jian Irish, Ph.D., M.B.A., as Chief Executive Officer, emphasizing a commitment to delivering curative genetic medicines [12] - Metagenomi Therapeutics aims to leverage its proprietary gene-editing technologies to expand its pipeline and address various genetic disorders [9][10]

Core Insights - Metagenomi, Inc. is set to present new preclinical data on APOC3 at the upcoming Nature Conference, highlighting its collaboration with Ionis Pharmaceuticals [1][2] - The company focuses on developing curative genetic medicines through proprietary genome editing technologies, aiming to address various genetic mutations [2] - Metagenomi's lead program, MGX-001, shows a promising preclinical profile for treating hemophilia A, potentially offering lifelong protection from bleeding events [3] Company Overview - Metagenomi is an in vivo genome editing company that utilizes metagenomics to develop novel editing tools for correcting genetic mutations [2] - The company aims to expand its pipeline by leveraging its genetic editing capabilities for site-specific deletion, integration, and correction [2] Product Development - MGX-001 is designed to provide a one-time treatment for hemophilia A, demonstrating competitive potential against existing treatment options [3] - The company is also exploring treatments for other secreted protein deficiencies and cardiometabolic diseases using its genome integration system [3]